IGM Biosciences, Inc.
IGMSNASDAQHealthcare
$1.27
+$0.00(+0.00%)
Market Cap$77498317
P/E Ratio—
52W High$22.5
52W Low$0.92
IGM Biosciences, Inc. (IGMS) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
IGMS · earnings · updated Jun 9, 2026
Latest Earnings
Q3 FY2025Report Date: Jul 31, 2025EPS Actual
$1.58
Est. -$0.30 · +626.7%
Revenue
$0.14B
Est. $0.00B · +4384.7%
Fiscal Period
Q3 FY2025
FY ends December
Report Date
Jul 31, 2025
After Market Close
▲ Beat EPS▲ Beat Revenue✓ 1-Quarter EPS Beat Streak
IGMS reports quarterly as a NASDAQ-listed Biotechnology company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
84
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
$78.12
Rev. $1025.0B
Days Away84
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.$78.12
Rev. Est.$1025.0B
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ▲ Q3 FY2025 | Jul 31, 2025 | -$0.30 | $1.58 | +626.7% | $0.14B | $0.00B | +4384.7% |
| ▼ Q2 FY2025 | May 13, 2025 | -$0.41 | -$0.86 | -109.8% | $0.00B | $0.00B | -88.3% |
| ▼ Q2 FY2025 | May 6, 2025 | -$0.45 | -$0.61 | -34.6% | $0.00B | $0.00B | -90.3% |
| ▼ Q4 FY2024 | Nov 8, 2024 | -$0.82 | -$1.01 | -23.2% | $0.00B | $0.00B | +91.1% |
| ▼ Q3 FY2024 | Aug 14, 2024 | -$0.04 | -$0.79 | -1991.0% | $0.00B | $0.05B | -97.7% |
| ▲ Q2 FY2024 | May 8, 2024 | -$0.84 | -$0.83 | +1.2% | $0.00B | $0.00B | -34.6% |
| ▲ Q1 FY2024 | Mar 7, 2024 | -$1.06 | -$1.01 | +4.7% | $0.00B | $0.00B | -6.9% |
| ▲ Q4 FY2023 | Nov 13, 2023 | -$1.25 | -$1.04 | +16.8% | $0.00B | $0.00B | -27.3% |
Q3 FY2025
Jul 31, 2025Beat
EPS Actual
$1.58
EPS Est.
-$0.30
EPS Surpr.
+626.7%
Revenue
$0.14B
Q2 FY2025
May 13, 2025Miss
EPS Actual
-$0.86
EPS Est.
-$0.41
EPS Surpr.
-109.8%
Revenue
$0.00B
Q2 FY2025
May 6, 2025Miss
EPS Actual
-$0.61
EPS Est.
-$0.45
EPS Surpr.
-34.6%
Revenue
$0.00B
Q4 FY2024
Nov 8, 2024Miss
EPS Actual
-$1.01
EPS Est.
-$0.82
EPS Surpr.
-23.2%
Revenue
$0.00B
Q3 FY2024
Aug 14, 2024Miss
EPS Actual
-$0.79
EPS Est.
-$0.04
EPS Surpr.
-1991.0%
Revenue
$0.00B
Q2 FY2024
May 8, 2024Beat
EPS Actual
-$0.83
EPS Est.
-$0.84
EPS Surpr.
+1.2%
Revenue
$0.00B
Q1 FY2024
Mar 7, 2024Beat
EPS Actual
-$1.01
EPS Est.
-$1.06
EPS Surpr.
+4.7%
Revenue
$0.00B
Q4 FY2023
Nov 13, 2023Beat
EPS Actual
-$1.04
EPS Est.
-$1.25
EPS Surpr.
+16.8%
Revenue
$0.00B
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2027 | $-0.72 | $-0.72 | $-0.72 | 1 |
| Q3 FY2027 | $-0.69 | $-0.69 | $-0.69 | 1 |
| Q2 FY2027 | $-0.67 | $-0.67 | $-0.67 | 1 |
| Q1 FY2027 | $-0.64 | $-0.64 | $-0.64 | 1 |
| Q4 FY2026 | $-0.61 | $-0.61 | $-0.61 | 1 |
| Q3 FY2026 | $-0.58 | $-0.58 | $-0.58 | 1 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2027 | $0.0B | $0.0B | $0.0B | 1 |
| Q3 FY2027 | $0.0B | $0.0B | $0.0B | 1 |
| Q2 FY2027 | $0.0B | $0.0B | $0.0B | 1 |
| Q1 FY2027 | $0.0B | $0.0B | $0.0B | 1 |
| Q4 FY2026 | $0.0B | $0.0B | $0.0B | 1 |
| Q3 FY2026 | $0.0B | $0.0B | $0.0B | 1 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▲ Q3 FY2025 | Jul 31, 2025 | +626.7% | $1.26 | $1.27 | +0.79% |
| ▼ Q2 FY2025 | May 13, 2025 | -109.8% | $1.19 | $1.15 | -3.36% |
| ▼ Q2 FY2025 | May 6, 2025 | -34.6% | $1.29 | $1.17 | -9.30% |
| ▼ Q4 FY2024 | Nov 8, 2024 | -23.2% | $14.37 | $13.03 | -9.32% |
| ▼ Q3 FY2024 | Aug 14, 2024 | -1991.0% | $8.88 | $8.72 | -1.80% |
| ▲ Q2 FY2024 | May 8, 2024 | +1.2% | $9.93 | $9.34 | -5.94% |
| ▲ Q1 FY2024 | Mar 7, 2024 | +4.7% | $12.22 | $12.13 | -0.74% |
| ▲ Q4 FY2023 | Nov 13, 2023 | +16.8% | $4.51 | $4.65 | +3.10% |
Q3 FY2025+0.79%
Report Date
Jul 31, 2025
EPS Beat/Miss
+626.7%
Price Before
$1.26
Price After
$1.27
Q2 FY2025-3.36%
Report Date
May 13, 2025
EPS Beat/Miss
-109.8%
Price Before
$1.19
Price After
$1.15
Q2 FY2025-9.30%
Report Date
May 6, 2025
EPS Beat/Miss
-34.6%
Price Before
$1.29
Price After
$1.17
Q4 FY2024-9.32%
Report Date
Nov 8, 2024
EPS Beat/Miss
-23.2%
Price Before
$14.37
Price After
$13.03
Q3 FY2024-1.80%
Report Date
Aug 14, 2024
EPS Beat/Miss
-1991.0%
Price Before
$8.88
Price After
$8.72
Q2 FY2024-5.94%
Report Date
May 8, 2024
EPS Beat/Miss
+1.2%
Price Before
$9.93
Price After
$9.34
Q1 FY2024-0.74%
Report Date
Mar 7, 2024
EPS Beat/Miss
+4.7%
Price Before
$12.22
Price After
$12.13
Q4 FY2023+3.10%
Report Date
Nov 13, 2023
EPS Beat/Miss
+16.8%
Price Before
$4.51
Price After
$4.65
Avg Beat Reaction-0.70%
Avg Miss Reaction-5.95%
Beat Rate4 / 8 quarters
Largest Move-9.32% (Q4 FY2024)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: IGMS ends December
IGM Biosciences, Inc. (IGMS) most recently reported earnings on July 31, 2025 for Q3 FY2025, posting EPS of $1.58 — beating the analyst consensus of $-0.30 by +626.7%. The next IGMS earnings date is expected around September 1, 2026.
Each quarter, investors track IGMS earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. IGMS revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
IGMS's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
IGMS earnings · 5 questionsIGM Biosciences, Inc.'s next earnings report is expected around September 1, 2026. IGMS typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; IGMS historically reports after market close (AMC).
IGMS earnings datewhen is IGMS earningsIGMS next earnings datewhen does IGMS report earningsIGMS earnings calendar
▸ Source: FMP · IGM Biosciences, Inc. SEC filings · US GAAP · IGM Biosciences, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 9, 2026